Prandial options to advance basal insulin glargine therapy: Testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: The GetGoal Duo-2 Trial

Diabetes Care

Volumn 39, Issue 8, 2016, Pages 1318-1328

  Rosenstock, Julio ^a   Guerci, Bruno ^b   Hanefeld, Markolf ^c   Gentile, Sandro ^d   Aronson, Ronnie ^e   Tinahones, Francisco J ^f   Roy Duval, Christine ^g   Souhami, Elisabeth ^g   Wardecki, Marek ^h   Ye, Jenny ^g   Perfetti, Riccardo ^g   Heller, Simon ⁱ  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b UNIVERSITÉ DE LORRAINE   (France)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e LMC DIABETES AND ENDOCRINOLOGY   (Canada)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^g SANOFI   (France)

^h Sanofi Pasteur   (Poland)

ⁱ UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN GLULISINE; LIXISENATIDE; METFORMIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PEPTIDE;

ACUTE PANCREATITIS; ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT WITHDRAWAL; VOMITING; AGED; AGONISTS; BIOASSAY; BODY MASS; BODY WEIGHT; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 2; MEAL; METABOLISM; MIDDLE AGED; POSTPRANDIAL STATE;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; MALE; MEALS; METFORMIN; MIDDLE AGED; OVERWEIGHT; PEPTIDES; POSTPRANDIAL PERIOD;

EID: 84980385742     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0014     Document Type: Article

References (22)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35:1364-1379
2. Riddle MC, Rosenstock J, Vlajnic A, Gao L. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes Metab 2014; 16:396-402
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38:140-149
5. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care 2010; 33:240-245
6. Ahrén B, Gautier JF, Berria R, Stager W, Aronson R, Bailey CJ. Pronounced reduction of postprandial glucagon by lixisenatide: a metaanalysis of randomized clinical trials. Diabetes Obes Metab 2014; 16:861-868
7. Lorenz M, Pfeiffer C, Steinsträsser A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes-relationship to postprandial glycemia. Regul Pept 2013; 185:1-8
8. Meier JJ GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8:728-742
9. Meier JJ, Rosenstock J, Hincelin-Méry A, et al. Contrasting effects of lixisenatide and liraglutide on post-prandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care 2015; 38: 1263-1273
10. Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013; 36:2489-2496
11. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26:3080-3086
12. Monnier L, Colette C. Addition of rapidacting insulin to basal insulin therapy in type 2 diabetes: indications and modalities. Diabetes Metab 2006; 32:7-13
13. Nathan DM, Zinman B, Cleary PA, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009; 169:1307-1316
14. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005; 28:2948-2961
15. Gallwitz B, Böhmer M, Segiet T, et al. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care 2011; 34:604-606
16. Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13:348-356
17. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M; Albiglutide Study Group. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009; 32:1880-1886
18. Raccah D, Lin J, Wang E, et al. Once-daily prandial lixisenatide versus once-daily rapidacting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. J Diabetes Complications 2014; 28:40-44
19. Diamant M, Nauck MA, Shaginian R, et al.; 4B Study Group. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 2014; 37:2763-2773
20. Rosenstock J, Fonseca VA, Gross JL, et al.; Harmony 6 Study Group. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care 2014; 37: 2317-2325
21. Mathieu C, Rodbard HW, Cariou B, et al.; BEGIN: VICTOZA ADD-ON (NN1250-3948) study group. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab 2014; 16:636-644
22. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281:E155-E161